TriangleMirdametinib (NCT06159166)
Mirdametinib trial for Neurofibromatosis Type 1 With Cutaneous Neurofibromas (NCT06159166). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with neurofibromatosis type 1 and cutaneous neurofibromas, benign tumors on or in the skin.
The idea: mirdametinib is a pill that blocks MEK, a signal that helps these tumors grow. Up to four dose regimens are tested, taken continuously or three weeks on and one week off.
The study first looks at safety to choose a recommended dose, then at how well it works.
This phase 1 and 2 study plans 24 patients. At Johns Hopkins in Baltimore, Carlos Romo leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.